An assessment of a drug for a rare muscular condition was removed from the website of the National Centre for Pharmacoeconomics, at the request of the Department of Health.
The new drug is for a condition called Duchenne Muscular Dystrophy (DMD), which can lead to scoliosis.
The recommendation from the NCPE is that the drug should not be covered by the HSE for the public unless its cost-effectiveness can be improved.
The NCPE provides independent assessments for the HSE on whether new drugs are cost-effective enough to be provided to the public.
NCPE Clinical Director Professor Michael Barry told RTÉ News that he agreed to remove the written assessment…